Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Other · Jun 2014 Brief report · Jun 2009 US FDA approves golimumab for treating three types of immune-related arthritis
Commentary · Feb 2009 Golimumab: a new anti-TNF agent on the horizon for inflammatory arthritis
Opinion · 31 Jan 2022 Biologic Medicines for Primary Resistant Framework Sicknesses
Review article · 8 Jul 2016 Biologic monotherapy for the treatment of rheumatoid arthritis
Methotrexate monotherapy for rheumatoid arthritis is considered efficacious and safe, but an
Review article · 2016 Central Nervous System Vasculitis Complicating Rheumatoid Arthritis in a Patient on a TNF Inhibitor: a Causal Association? Case Report and Systematic Review
Primary Angiitis of the Central Nervous System (PACNS) is a rare disease
Conference abstract · 16 Jun 2016 Use of biologic agents for rheumatic diseases in pregnancy
provides published data on use of biologic agents including etanercept, infliximab, adalimumab, certolizumab pegol, golimumab, tocilizumab, rituximab, anakinra and abatacept for rheumatic diseases during pregnancy
Research article · 2015 Budget Impact Analysis of Tofacitinib for treatment of Rheumatoid Arthritis
year time frame. The tumor necrosis factor inhibitors (anti-TNFs) adalimumab, etanercept, infliximab, golimumab and certolizumab were considered as comparators. The BIM tested two base-case scenarios: ?Base-case…
Editorial · 30 Dec 2023 The impact of biological therapy on bone in rheumatoid arthritis after three years: data from the Moroccan RBSMR registry
anti-CD 22), Group II (n= 21, anti-TNFi including infliximab, etanercept, adalimumab, and golimumab), and Group III (n=22, tocilizumab). 15.7% of patients received anti-osteoporotic treatment (AOT) with
Perspective · 24 Jun 2023 Emerging Novel Therapies for Ankylospondylitis
five TNF inhibitors for AS; Adalimumab (Humira), certolizumab (Cimzia), etanercept (Enbrel), infliximab (Simponi), and golimumab (Remicade) are some examples of anti-TNF medications. Trials are also being conducted with…
Mini review · 27 Apr 2023 TNF-α/hostile to TNF-α medicates and its impact on pregnancy results
birth) of utilizing hostile to TNF-α drugs (Infliximab, Etanercept and Adalimumab, Certolizumab and Golimumab) at present in the clinical examinations. In general, the most frequent adverse pregnancy outcomes
Research article · 29 May 2021 Treatment patterns and costs of patients with ankylosing spondylitis initiating biologic therapy in taiwan - a population-based analysis
were 430 as patients included in the biologic-initiators cohort (adalimumab = 191; etanercept = 122; golimumab = 177, etc.). Pre-Index utilization rates were significantly higher for biologic-initiators compared
Short communication · 9 Feb 2020 Secukinumab for recalcitrant Psoriatic Arthritis cases
TNFi for moderate-to-severe PsA was etanercept [8]. Nowadays, several bDMARDs(adalimumab, infliximab, golimumab, certolizumabpegol, ustekinumab, secukinumab, ixekizumab) and targeted synthetic DMARDs are already…
Case report · 1 Jul 2019 Good Response of Lupus Hepatitis to Mycophenolate Mofetil and Belimumab as of Lupus Exanthema to Rituximab: A Case Report
azathioprine (both removed due to non-response). Due to polyarthralgia methotrexate as well as golimumab were started. Despite good response, both drugs had to be stopped due to development
Research article · 17 Jan 2017 Access Pathway Delays and Burden of Disease for Patients with Severe Chronic Skin Conditions Requiring Systemic and Biologic Therapies at an Irish Dermatology Centre
retrospective study with analysis of patients on biologic agents: etanercept, adalimumab, ustekinumab, infliximab and golimumab for chronic dermatoses from 2006-2012. We identified 157 patients on biologics between this…
Other · 13 Jul 2016 New strategies for the treatment of inflammatory bowel diseases
news drugs in clinical practice. Two Phase III studies clearly indicate the interest of golimumab and vedolizumab in induction and maintenance treatment for ulcerative colitis patients. Soon it will
Review article · 6 Jul 2016 Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence
approved for use. This article summarizes the evidence for new TNFi (certolizumab and golimumab), B-cell-depleting therapy (rituximab), T-cell co‑stimulation modulating therapy (abatacept
Conference abstract · 16 Jun 2016 Current trends in the management of spondyloarthritis: It is not ankylosing anymore!
with 3308 participants) on the effect of anti-TNF drugs (adalimumab (HumiraÃ?®), etanercept (EnbrelÃ?®), golimumab (SimponiÃ?®) and infliximab (RemicadeÃ?®)) on ankylosing spondylitis. (Maxwell LG et al Cochrane review…
Research article · 2014 Modern Treatment of Rheumatoid Arthritis in Cows
rheumatoid arthritis. Future treatments are consist of biosimilars, alternative Tumor Necrosis Factor-α inhibitors (golimumab and certolizumab), and kinase inhibitors (tofacitinib and fostamatinib

